Fosamax and Osteonecrosis of the Jaw: Examining the Evidence for Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Assessment

General health and science communication has long served as a bridge between complex medical research and public understanding. In this tradition, the focus often begins with broad awareness of disease risk factors, gradually narrowing to specific exposures that warrant closer scrutiny. The legacy of such communication is to translate emerging evidence into actionable knowledge, particularly when a widely used therapeutic agent becomes associated with a serious adverse outcome. Within this framework, the discussion of bisphosphonate medications, such as Fosamax, and their potential link to osteonecrosis of the jaw (ONJ) represents a natural progression. Initially, the public health narrative centered on the benefits of these drugs for bone density. Over time, however, clinical observations prompted a shift toward examining unintended consequences. This pivot mirrors the evolution seen in occupational health, where a substance once considered safe may later be recognized as a hazard under certain conditions of exposure. The transition from a general health context to an occupational exposure concern is thus a matter of reframing the question: rather than asking whether a drug can cause harm in the general population, the inquiry becomes how cumulative or high-level exposure—whether through prescription use or workplace contact—might elevate risk. This shift in perspective allows for a more targeted investigation into the relationship between Fosamax exposure and the development of osteonecrosis of the jaw, without prematurely invoking specific disease mechanisms.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The clinical presentation of ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis typically involves clinical examination and imaging to confirm bone exposure and necrosis. The pharmacological mechanism linking Fosamax to ONJ involves its antiresorptive action. Bisphosphonates like alendronate inhibit osteoclast-mediated bone turnover, which can suppress normal bone remodeling. A multiscale characterization of jawbone has provided comprehensive information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the jawbone's unique structure and high remodeling rate may make it particularly vulnerable to the effects of bisphosphonate therapy.

Evidence from Clinical Studies on Risk and Duration of Use

Evidence from clinical studies indicates that the risk of ONJ increases with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation Considerations and Clinical Management

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk appears to increase with longer duration of use, as evidenced by the threefold increase after 2-3 years and eightfold increase after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remain low, and the condition is rare in the osteoporosis population. For patients who develop ONJ, discontinuation of Fosamax is recommended, and symptoms often resolve after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Rechallenge with the same or another bisphosphonate may lead to recurrence in a subset of patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. The label also advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that the background incidence of such symptoms in the studied populations was not significantly elevated by the drug.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone remodeling, and its use has been associated with osteonecrosis of the jaw (ONJ). The risk increases with longer duration of use, with studies showing a threefold increase after 2-3 years and an eightfold increase after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). ONJ presents as exposed, non-healing bone in the jaw, often triggered by dental procedures.

How common is ONJ in patients taking Fosamax for osteoporosis?

Absolute risks remain low, approximately 0.05% after 5 years of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/). The condition is rare in the osteoporosis population, but the risk is higher with prolonged use and in the presence of other risk factors such as invasive dental procedures, cancer, or concomitant therapies.

What should I do if I develop symptoms of ONJ while taking Fosamax?

If you develop symptoms such as jaw pain, swelling, or exposed bone, consult your healthcare provider. Discontinuation of Fosamax is recommended, and symptoms often resolve after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Avoid invasive dental procedures if possible, and maintain good oral hygiene.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.